| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Carolyn Beaver is Director at SONX, with reported holdings spanning 2 companies. Carolyn Beaver's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.5M at current prices.
Carolyn Beaver's largest disclosed position is in MXL as Director, worth about $2.1M. The MXL filings lean toward selling, a net 6,000 shares.
Carolyn Beaver has 27 Form 4 filings on record from December 2018 to June 2026, across 4 companies: Director at MediciNova (MNOV), 2020–2026; Director at MaxLinear (MXL), 2018–2026; Director at Sonendo (SONX), 2022–2024, and 1 more.
The 32 reported transactions were 23 option or other derivative awards, 5 option exercises, 3 stock awards and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $462K.
The only open-market sale was 6,000 shares of MXL at an average $76.96 on May 4, 2026, about $462K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | MXL Maxlinear, Inc. | Director | Sale+OE | 6,000 | $76.96 | $461,746.80 | -15.3% | -14.1% | - |